Journal article icon

Journal article

Rolling out the radical cure for vivax malaria in Asia: a qualitative study among policy makers and stakeholders

Abstract:
Introduction: Plasmodium vivax is the predominant cause of malaria in the Greater Mekong Subregion. To ensure safe treatment with primaquine, point-of-care glucose-6-phosphate dehydrogenase (G6PD) testing was rolled out in Cambodia at the health facility level, although most malaria patients are diagnosed in the community. The current study aims to explore the acceptability and feasibility of implementing community-level G6PD testing in Cambodia. Methods: Semistructured interviews and focus group discussions (FGD) were conducted. Across eight study sites in three provinces, 142 respondents, including policymakers, programme officers, healthcare providers and patients, participated in 67 interviews and 19 FGDs in 2022 and 2023. Data were analysed thematically using an adapted framework derived from Bowen et al’s feasibility framework and Sekhon et al’s acceptability framework. Results: All stakeholders attributed value to the intervention. Acknowledging an intervention’s different values can help discern policy implications for an intervention’s successful implementation. Building and maintaining confidence in the device, end users, infrastructure and health systems were found to be key elements of acceptability. In general, health centre workers and village malaria workers (VMWs) had confidence that VMWs could conduct the test and administer treatment given appropriate initial training, monthly refresher training and the test’s repeated use. More is required to build policymakers’ confidence, while some implementation challenges, including the test’s regulatory approval, stability above 30°C and cost, need to be overcome. Conclusion: Implementation of G6PD testing at the community level in Cambodia is an acceptable and potentially feasible option but requires addressing implementation challenges and building and maintaining confidence among stakeholders
Publication status:
Published
Peer review status:
Peer reviewed

Actions

Access Document

Files:
Publisher copy:
10.1186/s12936-021-03702-5

Authors

More by this author
Institution:
University of Oxford
Role:
Author
ORCID:
0000-0001-8981-3910
More by this author
Institution:
University of Oxford
Role:
Author
ORCID:
0000-0002-7380-1197
More by this author
Institution:
University of Oxford
Role:
Author
ORCID:
0000-0002-0282-6469


Publisher:
BioMed Central
Journal:
Malaria Journal More from this journal
Volume:
20
Issue:
1
Pages:
164-164
Article number:
164
Publication date:
2021-03-23
DOI:
EISSN:
1475-2875
ISSN:
1475-2875


Language:
English
Keywords:
Pubs id:
1170149
Local pid:
pubs:1170149
Source identifiers:
W3136902950
Deposit date:
2026-02-14
ARK identifier:
This ORA record was generated from metadata provided by an external service. It has not been edited by the ORA Team.

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP